Australia's most trusted
source of pharma news
Posted 17 December 2021 AM
With outcomes of the PBAC's November meeting due later today, Merck's lung cancer therapy Tepmetko is the only drug yet to be TGA approved among the 31 new listings requests, suggesting the company could miss a recommendation this time round.
Merck only received an orphan drug designation for the therapy in July for the treatment of non-small cell lung cancer (NSCLC) in patients with genetic MET alterations, although it also received a provisional determination on the same day, meaning it could be approved in quicker timeframe on the basis of preliminary clinical data.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.